Latest Administration News

EBR Systems plans to file a Changes Being Effected PMA supplement in the fourth quarter to make echo-induced pacing risks and their mitigations more prominent on WiSE System labelling. The FDA has aligned with the proposed path, but the filing and final labelling changes are still ahead.

Dataworks has secured firm commitments for a A$3.0 million placement and will seek up to a further A$1.24 million from shareholders to fund debt repayment, government contract mobilisation and commercial expansion. The raise gives the company more capital to pursue growth, but at a discount that will increase the share count and potentially add substantial option dilution.

EBR Systems’ new Santa Clara manufacturing facility has entered the FDA’s pre-approval inspection process, marking a key regulatory step for its wireless cardiac pacing business. The company continues to expect approval by the end of 2026, but the inspection does not yet amount to clearance.

Prescient Therapeutics has extended its Share Purchase Plan by three days after shareholders reported delays receiving application documents. The revised timetable places the offer’s results announcement just ahead of a planned briefing on the company’s PTX-100 development program.

Element 25 has started early site works at its Butcherbird Expansion Project in Western Australia, preparing the ground for a planned 1.1Mtpa manganese operation. The milestone shifts the project from planning towards physical construction, although the main construction package is yet to be awarded.

Netwealth will acquire AI advice platform Paradino for up to $29 million and invest a further $10 million to scale the business. The deal extends Netwealth beyond platform administration into advice production, while Paradino remains loss-making and separately reported.

PGG Wrightson delivered a sharp improvement in FY26 earnings, with Operating EBITDA up 15% to NZ$64.3 million and net profit rising 46% to NZ$15.6 million. The result supports a fully imputed 5.5 cents per share final dividend, although debt and GO-STOCK receivables have also expanded.

Benz Mining’s quarterly loss widened sharply as exploration spending surged at its Western Australian projects, but a subsequent C$148.02 million placement has given the company substantial funding to accelerate Glenburgh drilling. The project’s 10.1-12.0 million ounce Exploration Target remains conceptual rather than a Mineral Resource.

Imagion Biosystems has signed nanoComposix to resume GMP-aligned manufacturing of the MagSense nanoparticle core, a move designed to support its FDA-cleared HER2 breast cancer programme without the fixed cost of an in-house facility. The agreement improves manufacturing readiness, but its value, duration and production commitments remain undisclosed.

Dimerix has secured Mexican composition of matter protection for its Phase 2-ready kidney drug DMX-652 until June 2041. The grant expands the asset’s patent estate ahead of planned clinical testing in acute kidney injury, although it brings no new clinical data or regulatory approval.

Enova Mining reduced its half-year loss to $790,000, but an explicit going-concern warning puts future funding at the centre of its rare earth exploration story. The company ended June with $723,000 in cash while advancing several high-grade exploration targets across Brazil and Australia.

The Australian Taxation Office has confirmed the tax treatment of Brazilian Rare Earths’ Alurion Resources demerger, including roll-over relief and the split of shareholders’ cost bases. The ruling gives eligible BRE investors a clearer framework for handling the distribution in their tax records.